Yoshiki Nishizawa
Overview
Explore the profile of Yoshiki Nishizawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
308
Citations
5204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, et al.
Ther Apher Dial
. 2021 May;
26(1):220-228.
PMID: 34057286
Many reports have shown the therapeutic efficacy of LDL apheresis (LDL-A) in drug-resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results...
2.
Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M, et al.
Clin Chim Acta
. 2019 Aug;
498:101-107.
PMID: 31425674
With the aging of society, the number of osteoporosis-related fractures is increasing. Prevention of osteoporosis and maintenance of the quality of life of osteoporosis patients require early diagnosis, effective treatment,...
3.
Shoji T, Inaba M, Fukagawa M, Ando R, Emoto M, Fujii H, et al.
JAMA
. 2018 Dec;
320(22):2325-2334.
PMID: 30535217
Importance: Patients with chronic kidney disease have impaired vitamin D activation and elevated cardiovascular risk. Observational studies in patients treated with hemodialysis showed that the use of active vitamin D...
4.
Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y
J Bone Miner Metab
. 2018 Dec;
37(4):730-740.
PMID: 30523414
Limited data are available on the safety and efficacy of anti-resorptive agents, particularly once-monthly bisphosphonates, for use in osteoporotic patients with chronic kidney disease (CKD). We conducted a post hoc...
5.
Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al.
Curr Med Res Opin
. 2018 Jul;
35(3):447-454.
PMID: 29986611
Objective: Very few reports have described changes in bone mineral density (BMD) with long-term, once weekly administration of elcatonin, and its effects in reducing incident fractures remain unverified. Therefore, the...
6.
Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y
BMC Nephrol
. 2017 Feb;
18(1):66.
PMID: 28201994
Background: The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from...
7.
Watanabe Y, Akizawa T, Saito A, Gejyo F, Suzuki M, Nishizawa Y, et al.
Ther Apher Dial
. 2016 Dec;
20(6):598-607.
PMID: 27928910
Progression of anemia in patients with chronic kidney disease (CKD) is associated with an increased risk of death and hospitalization. It is not sufficiently clear whether treating renal anemia with...
8.
Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, et al.
Nephron Extra
. 2015 Nov;
5(2):58-66.
PMID: 26557843
Background/aims: LDL apheresis (LDL-A) is used for drug-resistant nephrotic syndrome (NS) as an alternative therapy to induce remission by improvement of hyperlipidemia. Several clinical studies have suggested the efficacy of...
9.
Inoue D, Muraoka R, Okazaki R, Nishizawa Y, Sugimoto T
Calcif Tissue Int
. 2015 Oct;
98(2):114-22.
PMID: 26466937
Many osteoporotics have comorbid diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DL). However, whether such comorbidities alter response to anti-osteoporotic treatment is unknown. We did post hoc analyses of combined...
10.
Kobayashi I, Ishimura E, Hirowatari K, Tsuchida T, Nishihira A, Shima H, et al.
NDT Plus
. 2015 May;
2(5):373-5.
PMID: 25949347
A renal biopsy was performed in a 47-year-old man with haemophilia A. Thirty minutes after administration of an intravenous bolus of 4000 units of recombinant factor VIII, which increased the...